

# Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

NCT06596694

---

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Merck Sharp & Dohme LLC
Enrollment	180 participants

## Key Eligibility Criteria

---

### Inclusion (7)

- Has one of the following cancers:
- Unresectable or metastatic colorectal cancer.
- Advanced and/or unresectable biliary tract cancer (BTC)
- Hepatocellular carcinoma (HCC) not amenable to locoregional therapy
- Locally advanced unresectable or metastatic gastroesophageal cancer

... and 2 more (see full listing online)

### Exclusion (6)

- Has a history of (noninfectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or has current ILD or pneumonitis, and/or suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening
- Has clinically severe respiratory compromise (based on the investigator's assessment) resulting from intercurrent pulmonary illnesses
- Has evidence of any leptomeningeal disease
- Has clinically significant corneal disease
- Has uncontrolled, significant cardiovascular disease or cerebrovascular disease

... and 1 more (see full listing online)

## Locations (62 total)

---

UCLA Hematology Oncology Santa Monica ( Site 1205), Santa Monica, California, United States

University of Colorado Cancer Center ( Site 1200), Aurora, Colorado, United States

Sibley Memorial Hospital ( Site 1208), Washington D.C., District of Columbia, United States

... and 59 more locations